Home
overview

SMi presents its 13th annual Parallel Trade conference, taking place in London on the 5th-6th of February 2019. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade.

The 2019 event will hold a particular place of significance due to Brexit and the UK officially leaving the EU on the 29th of March 2019. As such, the UK will no longer be part of the EU free market; hence, having a significant impact on parallel trade.

Furthermore, the FMD (Falsified Medicines Directive) will be coming into effect in February 2019. This conference will give companies affected the perfect opportunity to discuss and consider the impact that the FMD implementation will have on their practices and on the market.
 

This conference is a must-attend show for anyone involved in the parallel trade industry within pharmaceuticals and life sciences. Attending the show gives you the chance to interact with and discuss common issues with people involved in all the areas of the parallel trade industry to further strengthen your industry knowledge and approaches.

 

  • Partake in a platform discussion inclusive of all different facets of parallel trade in order to analyse the overall state of the market
  • Learn about the effects and impact of the impending FMD deadline to your company practices
  • Collaborate and explore ideas of how Brexit will impact the EU market and affect parallel trade practices overall
  • Discover issues surrounding competition laws and how this affects your business practices

 

ABACUS MEDICINE A/S; Abbvie Deutschland GmbH & Co. KG; ABPI; Aeterna Zentaris GmbH; Amgen ; APM Health Europe; Apotek Hjärtat AB; Arnold & Porter Kaye Scholer LLP; Arnold and Porter Kaye Scholer LLP; Astellas Pharma Ltd; ASTRAZENECA; AstraZeneca Czech Republic; Bristol Myers Squibb; Cartermatic Trading Enterprise; Chiesi Farmaceutici SpA; Clinical Insights; Clinigen Group; Daiichi Sankyo Europe GmbH; Diamond BioPharm Ltd; Durbin Plc; Ema; Europe Economics; European Alliance for Access to Safe Medicines; European Association of Euro-Pharmaceutical Companies ; Ferring Pharmaceuticals; Ferring Pharmaceuticals Ltd; Gilead Sciences Ltd; Grunenthal GmbH; H.Lundbeck; Idea Medica Limited; IMS Health GmbH & Co. OHG; IQVIA; Janssen Pharmaceutica NV; Johnson and Johnson ; Kantar Health; Kantar Health GmbH; LEO Pharma; medac GmbH; MHRA; MPA Business Services Ltd; Napp Laboratories; NOVARTIS PHARMA AG; Novartis Pharmaceuticals UK Ltd; NOVARTIS TURKEY; Novo Nordisk Pharma AG; Nupharm Laboratories Ltd; Omnia Läkemedel; Pharm-in, spol . S.R.O; Phoenix Healthcare Distribution Limited; QuintilesIMS; Ratiopharm GmbH; Research Health; Shire Pharmaceuticals Limited; Smith & Nephew; Sobi; Sunovion Pharmaceuticals Europe Ltd.; Swedish Orphan Biovitrum AB (publ); Takeda Pharmaceuticals International AG; Teva UK Limited; Tioluxe Pte Ltd; Vertex Pharmaceuticals (Europe) Ltd; Vifor Pharma Ltd.;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Heinz Kobelt

Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
View Bio

9:10 The fundamentals of parallel trade

Eric Noehrenberg

Eric Noehrenberg, Director Market Access, Edwards Life Sciences

  • The concepts behind the practice and specific ways of working
  • How a parallel trading business is run and the backing rationale
  • Specialisation and regional considerations
  • 9:50 The impact of parallel trade on patient safety

    Nerea Blanque

    Nerea Blanque, Senior Global Market Access and Pricing Manager, Almirall

  • Parallel trade management to ensure patient safety
  • Case study presenting a case of patient safety issues
  • The creation of shortages through the parallel export of medicines from states with lower costing medicines 
  • Would there be any way to change the market dynamic to reduce the level of shortages
  • 10:30 Morning Coffee

    11:00 Patients First

    Felipe Florez-Arango

    Felipe Florez-Arango, CFO, Allergan

  • Patients: Centre stage of everything we do / should do
  • Integrity of the Supply Chain
  • End-to-End supply chain: A MUS, not an option
  • 11:40 The economic impact of parallel trade on consumers – will Brexit make a difference?

    Deborah Drury

    Deborah Drury, Senior Consultant, Europe Economics
    View Bio

  • Effects of parallel trade on patients’ access to patented medicines.
  • Key risks and policy implications.
  • What opportunities and risks will Brexit offer?
  • 12:20 Latest Trends of European Parallel Trade

    Shabnam Hanassab

    Shabnam Hanassab, Engagement Manager, IQVIA
    View Bio

  • Parallel import trends in year 2018
  • Drivers of parallel trade across Europe
  • Brexit and possible impacts on supply chain
  • 13:00 Networking Lunch

    14:10 Product Proliferation: Entry deterrence, market shares and growth

    Farasat Bokhari

    Farasat Bokhari, Senior Lecturer in Economics, University of East Anglia
    View Bio

  • Strategic and non-strategic reasons for introducing additional drugs by a monopolist near the end of market exclusivity period for the original drug. 
  • Are these drugs introduced to deter generic entry, and if so, is it an effective strategy?
  • Post-entry, do additional product and pack variations by an incumbent help with revenue growth of the business unit? 
     
  • 14:50 The impact of parallel trading on pharmaceutical companies who distribute products both nationally and internationally

    Flemming  Wagner

    Flemming Wagner, CEO, ABACUS MEDICINE A/S
    View Bio

  • The business and economic impact of parallel trading on pharmaceutical companies and pharmaceutical manufacturers
  • The adjustment procedures which are put in place to avoid adverse effects
  • The creation of competition within the market and the pricing strategies that companies adopt
  • The assessment of demand based on the occurrence of parallel trading
  • 15:30 The European Medicines Verification System before the big bang! Are supply chain operators ready?

    Heinz Kobelt

    Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
    View Bio

  • System readiness: rollout of repository system across EEA area – experiences and last-minute obstacles
  • Company readiness: manufacturers, parallel distributors, wholesalers, hospital pharmacies and community pharmacists all had to prepare for compliance with FMD obligations – Lessons learnt
  • Funding of the EMVS and other remaining challenges
  • Implications on supply chain: is FDM disruptive? Are shortages to be feared? And Brexit is around the corner!
  • 16:10 Afternoon Tea

    16:40 PANEL DISCUSSION: The future of Parallel Trade and supply chain distribution:

  • The impact of parallel trade on the supply chain
  • The impact on pharmaceutical companies through the economic actions as a result
  • Future regulations and implementations which will impact existing models
  • The speculated effect of these changes within the market
  • Felipe Florez-Arango

    Felipe Florez-Arango, CFO, Allergan

    Vimal Unewal

    Vimal Unewal, Senior Manager In-Market Supply, Ferring Pharmaceuticals
    View Bio

    17:20 The practical impact of FMD implementation on trade

    Antonio Mendonca Alves

    Antonio Mendonca Alves, CEO, MD Pharma SA
    View Bio

  • A more practical outlook on the effect that the implementation of FMD will have on parallel trade, from a parallel trader’s perspective
  • The impact on day-to-day processes of wholesalers, parallel traders and pharmacies
  • The access of data generated towards member states
  • 18:00 Fighting fakes by raising public awareness

    Mike Isles

    Mike Isles, Executive Director, European Alliance for Access to Safe Medicines
    View Bio

  • The supply chains – legitimate and illegitimate
  • Demand side - fuelling the illegitimate Supply Chain
  • How can we monitor and manage the demand?
  • The role of the EU Commission and Member States in raising awareness
  • 18:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Heinz Kobelt

    Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
    View Bio

    9:10 The supply chain and the importance of track and trace along with the combination of systems

    Sigve Sivertsen

    Sigve Sivertsen, Head of Parallel Trade, Apotek Hjärtat AB
    View Bio

  • The inclusion of track and trace along with a unique identifier system
  • How does this integration of systems cause hindrances when the product travels through more complicated movements?
  • Are there any problem areas within the checking-in and out?
  • 9:50 The impact of parallel trade within the lower cost states

    Martin Slegl

    Martin Slegl, Regional Principal of East Europe, IQVIA
    View Bio

  • Overview of Eastern European (EE) pharma markets
  • Key difference in supply chain regulation in EE
  • Data availability in EE
  •  

    10:30 Morning Coffee

    11:00 Shortages of generic medicines: root causes and solutions

    Maarten Van Baelen

    Maarten Van Baelen, Market Access Director, Medicines for Europe
    View Bio

  • Drivers of medicines shortages in an off-patent, multi-source sector
  • Pressure of costly regulatory/quality procedures and cost-containment measures on generic medicines industry
  • Recommendations to prevent medicine shortages (addressing the root causes)
  • 11:40 PANEL DISCUSSION: Shortages – how and why do they occur?

  • The hypothesis behind where exactly within the market the shortages within regions are caused
  • The potential implementation of incentives towards companies to reduce this occurrence?
  • Would there be a way to track shortages in order to aid the reduction of them?

    Moderator: Heinz Kobelt, Director European Affairs, EAEPC

  • Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

    Maarten Van Baelen

    Maarten Van Baelen, Market Access Director, Medicines for Europe
    View Bio

    Martin Slegl

    Martin Slegl, Regional Principal of East Europe, IQVIA
    View Bio

    12:20 Review of recent excessive pricing and pay for delay cases and the implications for pricing

    Iona McCall

    Iona McCall, Senior Vice President, AlixPartners
    View Bio

  • Current regulatory framework for prices of branded medicines
  • Relationship between prices of branded medicines and parallel trade prices
  • Overview of recent branded pharma cases in UK and EC
  • Implications of recent cases for parallel trade prices
  • 13:00 Networking Lunch

    14:10 How to co-exist but do not break anti-trust rules – the margins for movement within competition law in line with the best business practices

    Miranda Cole

    Miranda Cole, Partner, Covington & Burling
    View Bio

  • The best way to establish patient level demand for a particular patient set, given the arguable changing goal-posts in the current landscape
  • Meeting the basic obligation of domestic demand whilst not catering towards extra-ordinary demand in order to keep in line with business sense
  • The strategy through which an interplay between bottom-bound capacity and a cap of supply is maintained
  • Applied examples of treatments where the difficulty of establishment of demand comes in i.e. with cancer treatments which could be used to treat multiple types of cancer and situations in which a company could be seen to be purposefully constraining a competitor’s behavior
  • 14:50 Is there a harmonised approach of Parallel Trade by authorities and courts in the EU?

    John Lisman

    John Lisman, Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    View Bio

  • The implementation of historic ECJ case law in the member states
  • Differences in impact of the Kohlpharma-ruling in the member states
  • Views of EU authorities
  • What are the consequences for the business?
  • 15:30 Exhaustion of Intellectual Property

    Christopher Stothers

    Christopher Stothers, Partner, Freshfields Bruckhaus Deringer LLP
    View Bio

  • Trademark law and the re-selling of products once it is within the marketplace
  • Re-packaging methods used within the re-selling of pharmaceutical products
  • The impact of new packaging requirements (i.e. safety features according to FMD: unique identifiers and anti-tampering devices) impact on re-packaging for parallel distribution
  • 16:10 Afternoon Tea

    16:40 The European Commission’s paper on the obligation of continuous supply

    Kasper Ernest

    Kasper Ernest, Secretary General, European Association of Euro-Pharmaceutical Companies
    View Bio

  • What the paper covers and the procedural practices for companies within the industry that it outlines
  • The impact of these practices on the market and company obligations towards the consumer
  • The rationale behind these policy choices and the potential procedural terminations they include
  • The link to the obligatory supply considerations along with tackling shortages
  • 17:20 Evolution of Parallel trade: scenarios and strategies

    Fabrizio Gianfrate

    Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara and Rome
    View Bio

  • Future impact of PT for manufacturer, wholesale and pharmacist
  • Possible win-win solutions
  • The Amazon effect on PT
  • EU and UK Payer evolution on PT
  • 18:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    David Guest

    David Guest

    Manager, Parallel Import Unit, MHRA
    Heinz Kobelt

    Heinz Kobelt

    Director European Affairs, European Association of Euro-Pharmaceutical Companies
    Mike Isles

    Mike Isles

    Executive Director, European Alliance for Access to Safe Medicines
    Miranda Cole

    Miranda Cole

    Partner, Covington & Burling
    Shabnam Hanassab

    Shabnam Hanassab

    Engagement Manager, IQVIA
    Vimal Unewal

    Vimal Unewal

    Senior Manager In-Market Supply, Ferring Pharmaceuticals

    Antonio Mendonca Alves

    CEO, MD Pharma SA
    Antonio Mendonca Alves

    As a graduate in “Business Administration” (at Universidade Católica Portuguesa) I began my career as a Tax Consultant at Deloitte in Lisbon. I soon felt the need to start-up my own projects, and so started-up a travel agency which was sold a year and a half later. Since then I have participated in starting-up small businesses in areas that range from food services to consultancy in modular construction.

    I first began in pharmaceutical distribution at Medipharm in 2008, a small distributor dedicated almost exclusively to parallel distribution. In 2010, we set-up MD PHARMA of which I have been general manager since the foundation. MD PHARMA is entirely dedicated to parallel distribution and is at this point a well positioned player in the Portuguese market, boasting a very solid reputation with all our business partners

    In addition, I am currently president of the board of APIEM (Portuguese association of importers and exporters of medicines) and board member of the EAEPC (European Association of Euro-Pharmaceutical Companies) in representation of Portugal.
     

    Christopher Stothers

    Partner, Freshfields Bruckhaus Deringer LLP
    Christopher Stothers

    Christopher is a recognized expert in parallel trade, with a particular focus on the pharmaceutical sector - his 2007 textbook, “Parallel Trade in Europe: Intellectual Property, Competition and Regulatory Law,” has been cited by the UK Supreme Court. Christopher is also an experienced litigator on cross-border patent disputes, other types of intellectual property, antitrust, pharmaceutical regulation, EU law and commercial disputes. He has taken cases before the First Tier Tribunal, the Upper Tribunal, the Patents County Court, the High Court, the Court of Appeal, the House of Lords, the Supreme Court, the European Patent Office, and the European Court of Justice.
     

    David Guest

    Manager, Parallel Import Unit, MHRA
    David Guest

    After more than 20 years as a Process Development chemist for a major pharmaceutical company, David joined one of the largest UK Parallel Importers as Regulatory Affairs Manager. His 5 year tenure gave him a good understanding of the restrictions and pressures on importers.
    Since joining MHRA as Manager of the Parallel Import Unit this industry experience has been beneficial in guiding changes to the internal assessment processes to provide a better service to industry while ensuring an appropriate focus on patient safety.
     

    Deborah Drury

    Senior Consultant, Europe Economics
    Deborah Drury

    Deborah Drury is a senior consultant at Europe Economics, an independent economics consultancy based in London and Brussels. Deborah has over 10 years’ experience as an economist, specialising in economic regulation, incentive design and public policy impact assessment across a range of sectors including healthcare and pharmaceuticals. Deborah has analysed the rationale for and impacts of healthcare professional regulation; regulatory approaches to telemedicine; and ways to combat the trade of counterfeit medicines in the EU.

    Eric Noehrenberg

    Director Market Access, Edwards Life Sciences
    Eric Noehrenberg

    Fabrizio Gianfrate

    Professor of Health Economics, University of Ferrara and Rome
    Fabrizio Gianfrate

    Phd and Masters in Health Economics (Rome, Stockholm, York). Master in Economic Journalism
    Actually: Full Professor of Health Economics, Market Access Consultant, Columnist
    Past: ex payer as AIFA member (pricing and reimbursement committee), Regional HTA Committees member (several Regions), Director at Ministry of Health (appointed), General Manager and Vice President of GSK Foundation Italy and of Angelini Foundation, several director roles in pharmaceutical industries, secondments in UK and US.
    Past Director of several magazines on healthcare and pharma, formers member of Farmindustria, Assobiotech, CENSIS, EFPIA, Federfarma
    Other: Actual Board Member of Italian Society of Pharmacoeconomics and Ethicals and Italian society of Healthcare studies)
    Author of more than 700 articles and 7 books

    Farasat Bokhari

    Senior Lecturer in Economics, University of East Anglia
    Farasat Bokhari

    Farasat Bokhari is a Senior Lecturer (Associate Professor) in the School of Economics and Centre for Competition Policy at the University of East Anglia. He is a health economist with a background in applied microeconomics and industrial organization, with a specialization in health policy. He has conducted research related to impact of public health financing on health outcomes as well as of other regulations on healthcare utilization. Dr. Bokhari’s research extends to competition and antitrust in the healthcare sector. His recent work is on welfare effects of new entrants, particularly of generic and follow-on (`me-too') drugs in the pharmaceutical markets. He has been active in studying firm strategies relating to pricing, launch of authorized generics, conducting pay-for-delay deals, and product differentiation and mergers and their impact on industry performance and structure.

    Felipe Florez-Arango

    CFO, Allergan
    Felipe Florez-Arango

    Flemming Wagner

    CEO, ABACUS MEDICINE A/S
    Flemming  Wagner

    53 years, married, 2 daughters, living in Copenhagen
    Nationality: Danish
    ABACUS MEDICINE A/S
    CEO and owner since 2006
    Supply of original medicines to hospitals and pharmacies in Europe.
    Turnover EUR 174 million in 2016
    Development and manufacturing of DayDose: “Supplements simplified” – www. daydose.com
    7 double Gazelle Award winner for fast growing companies in Denmark.
    “1000 companies to inspire Europe” award by LSEG
    Reddot international design award for DayDose
    +300 employees and subsidiaries in several EU countries
    RAMCON A/S
    CEO, 1993-2006
    Analytical and diagnostic equipment for hospitals and pharmaceutical industries
    Furthermore:
    Strategy Advisor and Examiner (7 years) and Mentor Leadership Program (3 years), Executive MBA
    Education:
    Executive MBA from Copenhagen Business School (CBS) in 2002
    • Winner of the award: MBA of the YEAR 2012
    Master of Science Biochemistry from Copenhagen University in 1993
    Summary:
    • Strategy and Implementation
    • Business Development and Sales
    • Management and leadership
    • Corporate strategy, growth

    Heinz Kobelt

    Director European Affairs, European Association of Euro-Pharmaceutical Companies
    Heinz Kobelt

    Heinz Kobelt, born 1947, holds the position of Director European Affairs of the EAEPC after having served as its Secretary General from February 2005 to April 2011.

    The European Association of Euro-Pharmaceutical Companies (EAEPC) is the representative voice of pharmaceutical parallel distribution in Europe. Through national association or individual company membership it encompasses some 88 firms from 23 countries in the European Economic Area (EEA).

    Before that, from 2001-2003, Heinz Kobelt was Head European Government Affairs of Novartis International, located in Brussels.

    From 1990 – 2001, Heinz Kobelt worked as an international public servant in the Secretariat of the European Free Trade Association (EFTA), where he participated in the negotiations of the EEA Agreement and held various positions as economist and policy analyst. He was stationed in Geneva, and from 1992 in Brussels.

    Between 1977 and 1990, he was a member of the Economics Administration of the Swiss Canton of St. Gallen, responsible for economic development and investment promotion.

    Heinz Kobelt holds a degree in economics (Dr. oec) from the University of St. Gallen, Switzerland.
     

    Iona McCall

    Senior Vice President, AlixPartners
    Iona McCall

    Iona is a competition economist with 16 years of experience advising clients on competition and regulatory matters. Iona has an established reputation for delivering rigorous economic analysis for clients, in particular with respect to anti-competitive agreements, abuse of dominance infringements, and associated private damages claims. She has acted for the UK, EC, Dutch and French competition authorities, as well as lawyers and businesses. Iona has worked across a range of sectors including transport, financial services, healthcare and pharmaceuticals. She holds an MSc Economics from the London School of Economics and a BSc (First) in economics and French from the University of Birmingham. Iona also spent a year studying economics at the Sorbonne in Paris.

    John Lisman

    Attorney, Consultant, Trainer, Lisman Legal Life sciences B.V.
    John Lisman

    John Lisman received master degrees in Pharmaceutical Sciences and Dutch Law from the Utrecht University. From 1992 until 2007, John was a civil servant in the Dutch Ministry of Health, Pharmaceutical Department, and the Dutch Medicines Evaluation Board as Policy Advisor. He was involved in EU legislation about medicinal products, medical devices, blood and blood products, cells and tissues and their implementation in Dutch law. He functioned as a member of many EU and international commissions and committees like the Pharmaceutical Committee and the EMA management board.
    Since 2007, John is attorney-at-law. He advices and represents clients from the area of pharmaceuticals, biologicals, medical devices and other medical products.
     

    John Schmidt

    Partner, Arnold and Porter
    John Schmidt

    Kasper Ernest

    Secretary General, European Association of Euro-Pharmaceutical Companies
    Kasper Ernest

    Kasper Ernest has worked in European affairs advocacy in Brussels since 2009. From 2009-2018 he was with the Confederation of Danish Enterprise, since 2015 serving as Director of the EU & International Department. He has also served as the Board Member of several EU-level business organisations, as a Member of the Danish Government’s Implementation Council, and was co-founder of the European Business Services Alliance. He joined the EAEPC as Secretary-General in April 2018. In addition, he is an external lecturer at Copenhagen Business School. He holds a Master’s degree in International Business and Politics from Copenhagen Business School and Singapore Management University.

    Kathy Harford

    Professional Support Lawyer, Arnold & Porter
    Kathy Harford

    Maarten Van Baelen

    Market Access Director, Medicines for Europe
    Maarten Van Baelen

    Medicines for Europe’s goal is to improve health by ensuring better access to treatment for patients in Europe and beyond. As Market Access Director for the Generic, Biosimilar and Value-Added medicines groups, the objective of Maarten’s team is to shape in the EU a dynamic and sustainable market environment.

    Maarten joined « Medicines for Europe » in 2011 as Medical Affairs Manager. In his life before the association, he worked in the pharmaceutical industry providing pharmacovigilance consultancy and in the medical device industry liaising with Key Opinion Leaders. He combined these roles while working weekends in a community pharmacy.

    Maarten is a pharmacist by education and holds an MBA from “Solvay Brussels School of Economics and Management” and “École des Ponts Paris Business School”.
     

    Martin Slegl

    Regional Principal of East Europe, IQVIA
    Martin Slegl

    Martin has over 9 years experience in the area of management consulting
    He has proven project experience across a variety of industries through Europe as he worked with Roland Berger Strategy Consultants and A.T. Kearney
    Martin holds CEMS Master's in International Management and Master’s in Business Economics degrees from ESADE and University of Economics in Prague
    Martin is responsible for consulting & PMR & Real Word Data activities in South East Europe
     

    Mike Isles

    Executive Director, European Alliance for Access to Safe Medicines
    Mike Isles

    Mike is Executive Director of the European Alliance for Access to Safe Medicines (EAASM). The EAASM is a pan-European patient safety organisation, bringing together all concerned with eliminating falsified medicines from the supply chain. With patient safety at its heart, the EAASM is also currently championing safe medical practices.

    Mike is also the Executive Director of the Alliance for Safe Online Pharmacy in the EU (ASOP EU). With over 30,000 fake pharmacy websites targeting Europe on any given day, this multisectoral organisation’s mission is to enable patients to buy their medicines online safely – where it is legal to do so.

    Mike is also European Medicines Partnership Director for International Health Partners a UK charity whose Queen’s Award for Enterprise for continuous Innovation, recognised the tremendous humanitarian work sourcing donated quality medicines from the healthcare industry and coordinating delivery via secure supply chain solutions to disaster-struck areas in close liaison with NGOs.
     

    Miranda Cole

    Partner, Covington & Burling
    Miranda Cole

    Miranda Cole, a partner based in Covington's Brussels and London offices, specializes in competition law, particularly in relation to complex collaborative arrangements, from structural transactions (and related merger control issues) to co-operative arrangements both between competitors and between companies active in related, but not overlapping markets.
    She focuses on advising companies active in the technology, software and life sciences sectors. She advises clients on competition issues raised by IP, data and technology, including access and licensing issues, standardization, remuneration and interoperability.
    Miranda has recently advised in connection with collaborative life sciences arrangements for Illumina, Takeda, AstraZeneca, Merck, UCB, Abbott, BMS, SK Biologics and Eli Lilly.
    Miranda was named among Politico’s “2017 Women Who Shape Brussels,” a group of “20 powerhouses driving debates and influencing policy.”
     

    Nerea Blanque

    Senior Global Market Access and Pricing Manager, Almirall
    Nerea Blanque

    Shabnam Hanassab

    Engagement Manager, IQVIA
    Shabnam Hanassab

    IQVIA’s expert and thought leader in European Parallel Trade dynamics, supply chain and distribution with several years of experience working in this field. Shabnam has developed in-depth expertise in pharmaceutical market dynamics and the increasing complexities of the trading environment. Shabnam is highly experienced on IQVIA’s data types, coverage and various supply chain offerings available centrally as well as locally, working with network of people within and outside organization. She has led several European supply chain consulting projects in the past few years.
    Shabnam holds BSc, MSc and PhD from University of London in Pharmaceutical and Computational Chemistry.
     

    Sigve Sivertsen

    Head of Parallel Trade, Apotek Hjärtat AB
    Sigve Sivertsen

    18 years’ experience from both the Norwegian and the Swedish Rx/parallel trade market.
    After 10 years in the Norwegian market as a Head of Rx with responsibility of Branded products, Generics, Parallel Import, Veterinary, Licensed products and export,
    Thereafter 8 years building up the Swedish Parallel Trade department for Sweden’s biggest private owned pharmacy chain, Apotek Hjärtat. Now Head of Rx with responsibility for all prescribed products.
     

    Tushar Patel

    Principal Consultant, Key Pharma
    Tushar Patel

    Vimal Unewal

    Senior Manager In-Market Supply, Ferring Pharmaceuticals
    Vimal Unewal

    Vimal Unewal is currently the Senior Manager for In-Market Supply for Ferring Pharmaceuticals, looking after the Parallel Trade across Europe. Vimal has 23 years of experience in supply chain and commercial across EMEA, Asian, Latin and North American markets for branded and generics pharmaceuticals, FMCG, and automotive. Vimal holds a B.Sc. in Business Management from Technical University of Lisbon and a frequent speaker at supply chain conferences. Vimal lives in Berkshire and he’s interested in music and table tennis.

    Supporters

    Workshops

    Parallel Trade & Brexit. What to expect?
    Workshop

    Parallel Trade & Brexit. What to expect?

    Holiday Inn Kensington Forum
    4th February 2019
    London, United Kingdom

    Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade
    Workshop

    Understanding IP, regulatory and competition law issues in pharmaceutical parallel trade

    Holiday Inn Kensington Forum
    4th February 2019
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Presentation by Neil Grubert

    Download

    Presentation by Dr. Christopher Stothers, Arnold & Porter

    Download

    Presentation by Farasat A.S. Bokhari, University of East Anglia

    Download

    Presentation by Sigve Sivertsen, Apotek

    Download

    Presentation by Antonio Mendonça Alves, MD PHARMA

    Download

    Presentation by Werner Berg, Baker McKenzie, Brussels

    Download

    Media Partners


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Pharmaceutical Outsourcing

    Supporters
    http://www.pharmoutsourcing.com

    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


    pharmanews hq

    Supporters
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/



    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    FirstWord

    Supporters
    http://www.firstwordgroup.com/

    FirstWord is an innovative industry intelligence leader serving over 200,000 Pharma Professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out